| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Immunochimie des Régulations Cellulaires et des Interactions Virales, Institut National de la Santé et de la Recherche Médicale, Unit 354, Centre INSERM, Hôpital Saint-Antoine, Paris, France
We herein analyzed the regulation of phosphatidylinositol 3-kinase (PI 3-kinase) activity by CR2 activated on B lymphocyte cell surface. We demonstrated that CR2 activation triggered in vivo PI 3-kinase activity and interaction of PI 3-kinase p85 subunit with a tyrosine-phosphorylated p95 component. The specificity of PI 3-kinase activity was controlled using wortmannin and LY294002. CR2 activation did not trigger tyrosine phosphorylation of PI 3-kinase p85 subunit, but induced direct interaction of tyrosine phosphorylated p95 with the Src homology 2 domain of p85 subunit, as shown using glutathione-S-transferase fusion proteins. Despite identical molecular masses, immunoblotting analysis demonstrated that tyrosine-phosphorylated p95 that interacted in vivo and in vitro with p85 was neither CD19, the 95-kDa proto-oncogene vav, nor Gab1 (a 95-kDa adaptor molecule). Furthermore, p95 tyrosine phosphoprotein also expressed in K562A cells (CR2+ CD19- cells) interacted with Src homology 2 domain of PI 3-kinase p85 subunit after CR2 activation. Activated CR2 did not interact directly with p85 subunit or tyrosine-phosphorylated p95. This suggests the presence of an intermediate molecule between activated CR2 and tyrosine-phosphorylated p95, which may be 3BP2. In addition, in contrast to CD19 activation, CR2 activation did not trigger interaction of CD19 or Vav with PI 3-kinase p85 subunit or coprecipitation of PI 3-kinase activity with CD19. Together, these data clearly demonstrated that CR2 activation triggered in vivo PI 3-kinase activation through a pathway distinct from that triggered through CD19 activation.
This article has been cited by other articles:
|
|
 |
|
  T. S. Kendrick, R. J. Lipscombe, O. Rausch, S. E. Nicholson, J. E. Layton, L. C. Goldie-Cregan, and M. A. Bogoyevitch Contribution of the Membrane-distal Tyrosine in Intracellular Signaling by the Granulocyte Colony-stimulating Factor Receptor J. Biol. Chem., January 2, 2004; 279(1): 326 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jozsi, J. Prechl, Z. Bajtay, and A. Erdei Complement Receptor Type 1 (CD35) Mediates Inhibitory Signals in Human B Lymphocytes J. Immunol., March 15, 2002; 168(6): 2782 - 2788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chakravarty, M. D. Zabel, J. J. Weis, and J. H. Weis Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation Int. Immunol., February 1, 2002; 14(2): 139 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Mogensen and S. R. Paludan Molecular Pathways in Virus-Induced Cytokine Production Microbiol. Mol. Biol. Rev., March 1, 2001; 65(1): 131 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Barel, M. Le Romancer, and R. Frade Activation of the EBV/C3d Receptor (CR2, CD21) on Human B Lymphocyte Surface Triggers Tyrosine Phosphorylation of the 95-kDa Nucleolin and Its Interaction with Phosphatidylinositol 3 Kinase J. Immunol., March 1, 2001; 166(5): 3167 - 3173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D’ADDARIO, A. AHMAD, J. W. XU, and J. MENEZES Epstein-Barr virus envelope glycoprotein gp350 induces NF-{kappa}B activation and IL-1{beta} synthesis in human monocytes-macrophages involving PKC and PI3-K FASEB J, December 1, 1999; 13(15): 2203 - 2213. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
